(4- ((1- (3- fluorophenyl)methyl)- 1H- indazol- 5- ylamino)- 5- methylpyrrolo(2,1- f)(1,2,4)triazin- 6- yl)carbamic acid 3-morpholinylmethyl ester

02/01/2012 - "BMS-599626 was generally well tolerated, with disease stabilization across a range of tumor types and doses."
10/15/2006 - "The preclinical data support the advancement of BMS-599626 into clinical development for the treatment of cancer."
10/15/2006 - "BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an additional mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth. "
10/15/2006 - "In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling. "
10/15/2006 - "BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors. "

09/01/2008 - "In a panel of five ovarian cancer cell lines, simultaneous treatment with the IGF-IR/InsR inhibitor, BMS-536924 and BMS-599626, resulted in a synergistic antiproliferative effect. "

08/01/2011 - "AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo."